FDA Approval Alert: The Need-to-Know | Enfortumab Vedotin-ejfv Plus Pembrolizumab for Urothelial Cancer

In April 2023, the FDA approved enfortumab vedotin-ejfv plus pembrolizumab as a combination therapy for patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.

Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Enfortumab/Pembrolizumab Dosing Schedule ‘Groundbreaking’ in Urothelial Cancer
Video
Apr 4, 2023 8:00 PM
Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.
Enfortumab Vedotin Combo Gets Accelerated FDA Nod for Urothelial Cancer
Article
Apr 3, 2023 9:09 PM
Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.